EGFR and neoplasm: Western blot and immunohistochemistry analyses demonstrated significantly reduced levels of phosphorylated EGFR and AKT in the primary tumor and metastatic tissues upon treatment with GZ17-6.02 (Supplementary Figure 6A and Supplementary Figure 7E–7F).